• Mpox, predominantly found in Central and West Africa, has recently led to significant outbreaks in non-endemic areas, including a major outbreak in the Democratic Republic of the Congo.

• The Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN) vaccine, approved for mpox and smallpox, has been evaluated for its effectiveness through a systematic review of observational studies published from January 2022 to February 2024.

• This review, which included 16 studies from high-income countries with varied designs and target populations, found that MVA-BN offers vaccine effectiveness (VE) against symptomatic mpox ranging from 35% to 86% after one dose and 66% to 90% after two doses in pre-exposure settings.

• For post-exposure prophylaxis, VE was observed at 78% and 89% for a single dose.

• Additionally, MVA-BN has been shown to reduce hospitalization risks and severity of symptoms, supporting its use in managing mpox outbreaks despite the studies' methodological diversity.

Click here to read more.